Biotechnology company Hyundai Bioscience (KOSDAQ:048410) on Wednesday announced plans to conduct a Phase 3 clinical trial for its oral COVID-19 treatment, Xafty, targeting high-risk patients with mild-to-moderate COVID-19.
The high-risk group includes those aged 60 and above, adults over 19 with underlying conditions such as diabetes, hypertension, cardiovascular disease, chronic heart and lung diseases, and immunocompromised individuals. These patients are at a higher risk of developing severe complications if infected with COVID-19.
Xafty has shown promising results in previous trials, particularly for high-risk groups. This new trial aims to address the urgent need for effective treatments for this vulnerable population, especially those unable to take Paxlovid due to drug interactions.
While maintaining the current process for emergency use authorisation for mild-to-moderate COVID-19 patients, Hyundai Bioscience will seek to expedite a Phase 3 trial exclusively for high-risk patients.
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults